PCM
LCTX icon

Poehling Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Poehling Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,143
Closed -$2K – 194
2018
Q2 		$2K Hold
1,143
– – ﹤0.01% 275
2018
Q1 		$3K Hold
1,143
– – ﹤0.01% 270
2017
Q4 		$2K Buy
+1,143
New +$2.5K ﹤0.01% 259

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IA
IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Poehling Capital Management's LCTX Position: Q3 2018 in Review

Poehling Capital Management sold out of Lineage Cell Therapeutics (LCTX) in Q3 2018, closing a stake of 1,143 shares — an estimated $2K sold.

Poehling Capital Management first reported a position in LCTX in Q4 2017 and held it in 3 quarters. The position peaked at $3K in Q1 2018. 106 funds tracked by Wall St. Rank hold LCTX as of Q3 2018.

  • Poehling Capital Management reported no remaining Lineage Cell Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Poehling Capital Management sold 1,143 Lineage Cell Therapeutics shares in Q3 2018, an estimated $2K.
  • Poehling Capital Management first reported a position in Lineage Cell Therapeutics in Q4 2017 and held it in 3 quarters.
  • Poehling Capital Management's Lineage Cell Therapeutics position peaked at $3K in Q1 2018.
  • 106 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2018.

Based on Poehling Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.